EFEKTIVITAS-BIAYA PENGGUNAAN BEVACIZUMAB DAN RANIBIZUMAB SEBAGAI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA PASIEN DENGAN GANGGUAN MATA: TINJAUAN SISTEMATIS
Anti-vascular endothelial growth factor (VEGF) injeksi intravitreal dapat digunakan untuk terapi pasien dengan gangguan mata. Obat anti-VEGF yang digunakan di antaranya bevacizumab, ranibizumab, aflibercept, dan brolucizumab. Obat tersebut termasuk ke dalam obat dengan biaya tinggi sehingga harus di...
Saved in:
| Main Authors: | Nur Sidik Cahyono, Elin Yulinah Sukandar |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Universitas Jenderal Achmad Yani
2024-04-01
|
| Series: | Kartika: Jurnal Ilmiah Farmasi |
| Subjects: | |
| Online Access: | https://kjif.unjani.ac.id/index.php/kjif/article/view/658 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series
by: Anil Babanrao Gangwe, et al.
Published: (2025-01-01) -
STUDI INTERAKSI OBAT-OBAT JANTUNG YANG DILAKUKAN TERHADAP ORANG SEHAT: TINJAUAN SISTEMATIS
by: Yunita Sumartin, et al.
Published: (2024-08-01) -
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01) -
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01) -
A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
by: Robert Hodgson, et al.
Published: (2025-01-01)